Lancet (London, England), 376 (9741), 595605
Unsurprisingly, not every new AOM asset delivered on those expectations in subsequent phase 2 or phase 3 trials, let alone setting ever more spectacular benchmarks for weight loss, while investors increasingly recognised the importance of a clean tolerability profile alongside compelling efficacy [1]
They are designed to do everything the GLP-1 hormone does, but they last longer
Pricing Disclaimer All pricing information referenced in this release is approximate, current as of publication date, and subject to change at any time without notice
Both Wegovy and liraglutide are GLP-1 receptor agonists, meaning they mimic the same gut hormone: GLP-1 (glucagon-like peptide-1)